Survival in primary antiphospholipid syndrome

Summary

The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predictors are poorly known. It was the study objective to evaluate the impact of baseline lupus anticoagulant assays, IgG anticardiolipin (aCL), plasma fibrinogen (FNG) and von Willebrand factor (VWF), platelets (PLT) and of genetic polymorphisms of methylenetetrahydrofolate reductase C677T, of prothrombin G20210A and of paraoxonase-1 Q192R on survival in primary APS (PAPS). Cohort study on 77 thrombotic PAPS and 33 asymptomatic carriers of aPL (PCaPL) seen from 1989 to 2015 and persistently positive for aPL as per annual review. At baseline all participants were tested twice for the ratios of kaolin clotting time (KCTr), activated partial thromboplastin time (aPTTr), dilute Russell viper venom time (DRVVTr), IgG aCL, FNG, VWF and once for PLT. All thrombotic PAPS were on warfarin with regular INR monitoring. During follow-up 11 PAPS deceased (D-PAPS) of recurrent thrombosis mostly arterial, despite adequate anticoagulation yielding an overall vascular mortality of 10 %. D-PAPS had the strongest baseline aPTTr and DRVVTr and the highest mean baseline IgG aCL, FNG, VWF and PLT. Cox proportional hazards model identified baseline DRVVTr and FNG as main predictors of mortality with adjusted hazard ratios of 5.75 (95 % confidence interval [CI]: 1.5, 22.4) and of 1.03 (95 %CI: 1.01, 1.04), respectively. In conclusion, plasma DRVVTr and FNG are strongly associated with the risk of vascular death in PAPS; while FNG lowering agents exist further research should be directed at therapeutic strategies able to dampen aPL production.

Keywords

Antiphospholipid syndrome - DRVVT - fibrinogen - mortality

• References

• 1 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
• 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 3 Khamashta MA, Cuadrado MJ, Mujic F. et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
• 4 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
• 5 Cervera R, Serrano R, Pons-Estel GJ. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011-1018.
• 6 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151.
• 7 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874.
• 8 Triplett DA, Brandt JT, Kaczor D. et al. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682.
• 9 Rosove MH, Ismail M, Koziol BJ. et al. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478.
• 10 Brancaccio V, Ames PR, Glynn J. et al. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul Fibrinolysis 1997; 08: 155-160.
• 11 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40: 163-171.
• 12 Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17: 237-246.
• 13 Margaglione M, D’Andrea G, d’Addedda M. et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 907-911.
• 14 Bub A, Barth SW, Watzl B. et al. Paraoxonase 1 Q192R (PON1–192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. Br J Nutr 2005; 93: 291-297.
• 15 Cox DR, Oakes D. Analysis of Survival Data: Taylor & Francis; Chapman and Hall/CRC. 1984
• 16 White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009; 28: 1982-1998.
• 17 Dall’Ara F, Reggia R, Taraborelli M. et al. Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus 2014; 23: 1255-1258.
• 18 Grika EP, Ziakas PD, Zintzaras E. et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516-523.
• 19 Turati F, Rossi M, Pelucchi C. et al. Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr 2015; 113 (Suppl. 02) S102-110.
• 20 Azzini E, Polito A, Fumagalli A. et al. Mediterranean Diet Effect: an Italian picture. Nutr J 2011; 10: 125.
• 21 Ruiz-Irastorza G, Egurbide MV, Ugalde J. et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
• 22 Ames PR, Pyke S, Iannaccone L. et al. Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients. Thromb Haemost 1995; 73: 768-773.
• 23 Rosner E, Pauzner R, Lusky A. et al. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57: 144-147.
• 24 Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993; 32: 568-573.
• 25 Manger K, Manger B, Repp R. et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065-1070.
• 26 Lockshin MD, Kim M, Laskin CA. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318.
• 27 Gebhart J, Posch F, Koder S. et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood 2015; 125: 3477-3483.
• 28 Ames PR, Margarita A, Delgado JAlves. et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208-214.
• 29 Maresca G, Di Blasio A, Marchioli R. et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.
• 30 Swarowska M, Polczak A, Pera J. et al. Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke. J Thromb Thrombolysis 2014; 38: 517-521.
• 31 Stack AG, Donigiewicz U, Abdalla AA. et al. Plasma fibrinogen associates independently with total and cardiovascular mortality among subjects with normal and reduced kidney function in the general population. QJM 2014; 107: 701-713.
• 32 Rudnicka AR, Mt-Isa S, Meade TW. Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost 2006; 04: 2405-2410.
• 33 Msaouel P, Lam AP, Gundabolu K. et al. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 2014; 99: 930-936.
• 34 Harrison MT, Short P, Williamson PA. et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax 2014; 69: 609-615.
• 35 Ikeda M, Furukawa H, Imamura H. et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 09: 287-291.
• 36 Ames PR, Tommasino C, D’Andrea G. et al. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies--prevalence and significance. Thromb Haemost 1998; 79: 46-49.
• 37 Delgado JAlves, Ames PR, Donohue S. et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-2694.
• 38 Ames PR, Nourooz-Zadeh J, Tommasino C. et al. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost 1998; 79: 447-449.
• 39 Cozzi L, Campolo J, Parolini M. et al. Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis. Mol Cell Biochem 2013; 374: 233-238.
• 40 Pengo V, Biasiolo A, Rampazzo P. et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999; 81: 256-258.